CATALIS is now implementing its new strategic plan with the creation of new advisory committees Since 2018, CATALIS’s operational activities have been guided essentially by an advisory committee composed of research centre administrators, pharmaceutical industry members, and government representatives. In 2021, given that the new strategic plan extends the scope of CATALIS’s actions, two new advisory committees will be created: a
CATALIS has great plans for the coming year. A message from the chairman of the CATALIS board of directors, Dr. Marc Rivière There is no doubt that this past year has been disconcerting and most unusual. Clinical research was confronted with substantial challenges that highlighted our system’s ability to adapt quickly and find innovative solutions. This exceptional situation caused us to
Boehringer Ingelheim and Sanofi Join the CATALIS Network New pharmaceutical industry partners are supporting CATALIS in making Quebec a world leader in clinical research. MONTREAL, May 20, 2021 —CATALIS Québec is proud to announce that two pharmaceutical companies, Boehringer Ingelheim and Sanofi, have joined its network of partners who are working together to support Quebec’s competitiveness in conducting clinical trials.
Diffusion of the updated “Standard legal clauses for information and consent forms for clinical trials” CATALIS Québec is pleased to announce that the revised version of the “Standard legal clauses for information and consent forms for clinical trials” has been published by the ministry of health and social services (MSSS). The original legal clauses for consent forms, published in 2016
CATALIS Quebec announces the rolls out the 2nd phase of Nagano clinical trial evaluation management system synchronization in the Quebec’s health and social services institutions Since 2010, majority of public institutions in Quebec’s health and social services network have gradually integrated the Nagano computer system, a platform that makes the administrative management of research projects, including clinical trials’ evaluation and
Appointment of Jacques Hendlisz as CATALIS Québec’s New Executive President CATALIS Quebec is proud to welcome Mr. Jacques Hendlisz to the organization as its new Executive President, effective April 1, 2020. Mr. Hendlisz is widely recognized for his extensive experience in the management of both research and hospital facilities. He served as the Douglas Institute’s Director General from 1994 to
The Quebec Government’s 2020–2021 budget, tabled yesterday by Minister of Finance Éric Girard, mentions investments in the field of clinical research, a commitment that was favourably received by CATALIS Québec’s board of directors.
CATALIS Québec launches a promotional campaign to demonstrate Quebec’s expertise in the conduct of early-phase clinical trials and to encourage new partnerships between the biopharmaceutical industry and university research centres.
CATALIS’s public and private partners join forces to make Quebec a global leader in the conduct of early-stage clinical trials.
How to propel Quebec to global leadership in early clinical research? Dr. Marc Rivière, the new chair of the board of directors of CATALIS Quebec, shares his vision.
Novartis and Roche Join the CATALIS Initiative Industry partnership will help establish Quebec as a global leader in early stage clinical research MONTREAL, February 6, 2019— The CATALIS initiative is proud to announce that pharmaceutical companies Novartis and Roche have joined its partner network. A mere two years after its creation, CATALIS Québec has succeeded in mobilizing Quebec’s key players
The CATALIS initiative celebrates new partners Private and public funding provide essential support and highlight Quebec’s role in the field of early stage clinical trials BOSTON, June 5th, 2018 – A year following its launch at the BIO conference in 2017, the CATALIS initiative is today proud to announce the arrival of new partners, both financial and medical, which will further
Progression of Quebec’s world-class Early Clinical Research Ecosystem Merck Canada provides financial and expert support to CATALIS MONTREAL, Quebec (May 9, 2018) – CATALIS is proud to announce that Merck Canada confirms financial and expert support for its early clinical research initiative. This support from Merck Canada contributes to the promotion of this world-class field of research in Quebec. “At
Successful start for CATALIS: initiative gains momentum, strengthening interest in the life sciences ecosystem MONTRÉAL (Quebec), October 25, 2017 —CATALIS presented its five-year plan to their partners’ that will set in motion the initiative announced in the Quebec government’s 2017-2027 Québec Life Sciences Strategy. The mission of CATALIS Quebec Clinical Trials, formerly known as the Early Stage Clinical Trials (ESCT) initiative,
Danika Laberge named general manager of CATALIS MONTRÉAL (Québec) July 21, 2017 — The CQDM and CATALIS’ executive committee are announcing that Ms. Danika Laberge has been named the organization’s Manager General. “It is with great pleasure that CATALIS’ executive committee has appointed Danika Laberge to the position of Manager General of CATALIS”, stated Diane Gosselin, CQDM’s President and Chief
During the recent BIO International Convention, Gaétan Barrette, Minister of Health and Social Services, announced that the Québec government will be contributing $5.3 million to the early clinical research initiative